LEK 8829

Drug Profile

LEK 8829

Latest Information Update: 10 Dec 2007

Price : $50

At a glance

  • Originator LEK
  • Class Antipsychotics; Ergolines; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D2 receptor antagonists; Serotonin 1A receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 23 Dec 2002 LEK has been acquired by Novartis
  • 07 Jun 1995 A preclinical study has been added to the pharmacodynamics section
  • 21 Nov 1994 Preclinical development for Psychotic disorders in Slovenia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top